Buscar
Conoce más de nuestros profesores:
Learn more about our outstanding professors
Conoce más de nuestros profesores:
Learn more about our Faculty:
Conoce más de nuestros profesores:
Since its foundation, Tecnológico de Monterrey has defined the regulations that guide its students, regarding the expected academic standards and conduct both inside and outside the classroom.
In this way, the Institution, committed to academic quality, disseminates its governing regulations among students and the community, within the framework of the principles and values described in the Mission.
Tuition/A Bolsa de Estudos
Vida Estudiantil
Guiding documents
In order to obtain an undergraduate degree at Tecnológico de Monterrey, students are required to:
1. Have fulfilled, in accordance with the effective regulations, the preliminary academic requirements of the corresponding curriculum, by means of the relevant placement exams or remedial courses.
2. Have completed all the courses in the relevant curriculum either by passing all of them at Tecnológico de Monterrey, or by obtaining revalidation or equivalency agreements, in conformity with the corresponding regulations, for some of the courses with studies completed at other institutions and passing the remaining courses at Tecnológico de Monterrey.
3. Have completed and passed at Tecnológico de Monterrey at least 50% of the courses that comprise the curriculum. This rule can be flexible for programs that, through an agreement, are created in conjunction with other universities.
4. Have completed their social service in compliance with the legal precepts in force and the corresponding social service regulations.
5. Have taken the General Undergraduate Exit Exam of the National Center for the Evaluation of Higher Education to evaluate the knowledge and skills acquired during their undergraduate program. This requirement applies only to students from the undergraduate programs for which these exams exist. The result of this exam will be recorded on the student’s transcript. Students from the undergraduate programs that do not have a CENEVAL exit exam must take the capstone exams designed for this purpose. This requirement applies only to students from the majors for which these exams exist.
6. Demonstrate a B2 level of proficiency in the English language according to the Common European Framework of References for Languages (CEFR) in one of the tests authorized by the Institution.
Semester-based calendars
Becas y Préstamos Educativos
Regístrate aquí
Al ingresar tus datos, recibirás información y atención personalizada. ¡Te esperamos!

En el Tec creemos en tus sueños y queremos impulsarlos.
Tan solo durante el semestre agosto – diciembre 2021 tenemos un total de:
30,400
alumnos becados.
Esto representa el 50.5% de los alumnos durante ese periodo.
Gracias a su talento y a la comunidad de donantes de nuestra institución, nuestros estudiantes acreedores a algún tipo de beca fueron beneficiados de la siguiente forma:
Beca Socieconómica
57.7%
Beca Talento Académico
26.2%
Beca Talento Estudiantil
8.91%
Líderes del Mañana
3.38%
Becas Talento Emprendedor
0.4%
Beca Talento Creativo
0.1%
Otras becas
3.3%
Other Financial Support per Campus
Monterrey

Richard Willson
Distinguished Visiting Professor in Biotechnology Engineering
Institute for Obesity Research and the School of Medicine and Health Sciences
Expertise
Medical diagnostics
Molecular biology
Bioseparations
Immunochromatographic diagnostics
Process analytical technology (PAT)
Overview
Dr. Richard Willson has an extensive career at the University of Houston, where he is Huffington-Woestemeyer Professor of Chemical and Biomolecular Engineering and Biochemistry. He is also Co-Principal Investigator of the U.S. FDA's Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC). He has been an affiliate in the Quantitative and Computational Biology program at Baylor College of Medicine since 2008 and a prominent senior affiliate member in the Cancer program at the Houston Methodist Research Institute since 2007. He was theme leader in Diagnostics at the NIH Western Regional Center of Excellence in Biodefense and Emerging Infectious Diseases.
Richard Willson’s work focuses on the development of diagnostics for infectious diseases and metabolic disorders and the development of new pharmaceuticals. He and his research group work on biomolecular recognition using monoclonal antibodies and aptamers. They explore the techniques of expression, mutagenesis, fluorescence anisotropy (kinetics), and titration calorimetry.
In the area of bioseparations, his recent work focuses on antibody purification. In the area of molecular diagnostics and sensors, he is using computer technology to identify viruses vs. human DNA. He is also working on a diagnostic that uses a method similar to glow-in-the-dark materials for easier home-based detection by ultra-sensitive lateral flow immunoassays.
Back in 2012 and due to his expertise in nucleic acid purification, he was selected to serve on the founding Technical Advisory Board of Moderna, Inc., which later developed the mRNA-based vaccine for COVID-19.
Richard Willson joined Tecnológico de Monterrey as a Distinguished Visiting Professor in Biotechnology Engineering for the Institute for Obesity Research and the School of Medicine and Health Sciences.
Education and Training
- Postdoctoral fellow, Biology, Massachusetts Institute of Technology (MIT)
- Ph.D., Chemical Engineering, Massachusetts Institute of Technology (MIT)
- M.Sc., Chemical Engineering, California Institute of Technology (Caltech)
Publications
-
Goux, Heather & Vu, Binh & Wasden, Katherine & Alpadi, Kannan & Kumar, Ajay & Kalra, Bhanu & Savjani, Gopal & Brosamer, Kristen & Kourentzi, Katerina & Willson, Richard. (2023). Development of a quantitative fluorescence lateral flow immunoassay (LFIA) prototype for point-of-need detection of anti-Müllerian hormone. Practical Laboratory Medicine. 35. e00314. 10.1016/j.plabm.2023.e00314.
-
Lei, Rongwei & Vu, Binh & Kourentzi, Katerina & Soomro, Sanam & Danthanarayana, Adheesha & Brgoch, Jakoah & Nadimpalli, Suma & Petri, Michelle & Mohan, Chandra & Willson, Richard. (2022). A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. Frontiers in Immunology. 13. 10.3389/fimmu.2022.1044743.
-
Nandy, Suman & Crum, Mary & Wasden, Katherine & Strych, Ulrich & Goyal, Atul & Maranholkar, Vijay & Mo, William & Vu, Binh & Kourentzi, Katerina & Willson, Richard. (2022). Protein A–Nanoluciferase fusion protein for generalized, sensitive detection of immunoglobulin G. Analytical Biochemistry. 660. 114929. 10.1016/j.ab.2022.114929.
-
Ortiz-Martinez, Margarita & González-González, Mirna & Martagon, Alexandro & Hlavinka, Victoria & Willson, Richard & Rito-Palomares, Marco. (2022). Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Current Diabetes Reports. 22. 10.1007/s11892-022-01453-4.
-
Chavan D, Chen H, Crum M, Vu B, Safari M, Smith M, Vekilov P, Conrad JC, Kourentzi K, Willson RC., "Neutral DNA-avidin nanoparticles as ultrasensitive reporters in immuno-PCR." Analyst. doi: 10.1039/d0an00134a., 2020

Richard Willson
Profesor Visitante Distinguido
en Ingeniería Biotecnológica
Instituto de Investigación sobre Obesidad y la Escuela de Medicina y Ciencias de la Salud
Expertise
Diagnósticos médicos
Biología molecular
Bioseparaciones
Diagnóstico inmunocromatográfico
Tecnología analítica de procesos (PAT, por sus siglas en inglés)
Overview
Dr. Richard Willson has an extensive career at the University of Houston, where he is Huffington-Woestemeyer Professor of Chemical and Biomolecular Engineering and Biochemistry. He is also Co-Principal Investigator of the U.S. FDA's Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC). He has been an affiliate in the Quantitative and Computational Biology program at Baylor College of Medicine since 2008 and a prominent senior affiliate member in the Cancer program at the Houston Methodist Research Institute since 2007. He was theme leader in Diagnostics at the NIH Western Regional Center of Excellence in Biodefense and Emerging Infectious Diseases.
Richard Willson’s work focuses on the development of diagnostics for infectious diseases and metabolic disorders and the development of new pharmaceuticals. He and his research group work on biomolecular recognition using monoclonal antibodies and aptamers. They explore the techniques of expression, mutagenesis, fluorescence anisotropy (kinetics), and titration calorimetry.
In the area of bioseparations, his recent work focuses on antibody purification. In the area of molecular diagnostics and sensors, he is using computer technology to identify viruses vs. human DNA. He is also working on a diagnostic that uses a method similar to glow-in-the-dark materials for easier home-based detection by ultra-sensitive lateral flow immunoassays.
Back in 2012 and due to his expertise in nucleic acid purification, he was selected to serve on the founding Technical Advisory Board of Moderna, Inc., which later developed the mRNA-based vaccine for COVID-19.
Richard Willson joined Tecnológico de Monterrey as a Distinguished Visiting Professor in Biotechnology Engineering for the Institute for Obesity Research and the School of Medicine and Health Sciences.
Education and Training
- Postdoctoral fellow, Biology, Massachusetts Institute of Technology (MIT)
- Ph.D., Chemical Engineering, Massachusetts Institute of Technology (MIT)
- M.Sc., Chemical Engineering, California Institute of Technology (Caltech)
Publications
-
Goux, Heather & Vu, Binh & Wasden, Katherine & Alpadi, Kannan & Kumar, Ajay & Kalra, Bhanu & Savjani, Gopal & Brosamer, Kristen & Kourentzi, Katerina & Willson, Richard. (2023). Development of a quantitative fluorescence lateral flow immunoassay (LFIA) prototype for point-of-need detection of anti-Müllerian hormone. Practical Laboratory Medicine. 35. e00314. 10.1016/j.plabm.2023.e00314.
-
Lei, Rongwei & Vu, Binh & Kourentzi, Katerina & Soomro, Sanam & Danthanarayana, Adheesha & Brgoch, Jakoah & Nadimpalli, Suma & Petri, Michelle & Mohan, Chandra & Willson, Richard. (2022). A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. Frontiers in Immunology. 13. 10.3389/fimmu.2022.1044743.
-
Nandy, Suman & Crum, Mary & Wasden, Katherine & Strych, Ulrich & Goyal, Atul & Maranholkar, Vijay & Mo, William & Vu, Binh & Kourentzi, Katerina & Willson, Richard. (2022). Protein A–Nanoluciferase fusion protein for generalized, sensitive detection of immunoglobulin G. Analytical Biochemistry. 660. 114929. 10.1016/j.ab.2022.114929.
-
Ortiz-Martinez, Margarita & González-González, Mirna & Martagon, Alexandro & Hlavinka, Victoria & Willson, Richard & Rito-Palomares, Marco. (2022). Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Current Diabetes Reports. 22. 10.1007/s11892-022-01453-4.
-
Chavan D, Chen H, Crum M, Vu B, Safari M, Smith M, Vekilov P, Conrad JC, Kourentzi K, Willson RC., "Neutral DNA-avidin nanoparticles as ultrasensitive reporters in immuno-PCR." Analyst. doi: 10.1039/d0an00134a., 2020